{
    "Trade/Device Name(s)": [
        "CONTOUR\u00ae NEXT ONE Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Ascensia Diabetes Care",
    "510(k) Number": "K210687",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191286"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "March 9, 2021",
    "Summary Letter Received Date": "March 10, 2021",
    "Submission Date": "August 11, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "CONTOUR\u00ae NEXT ONE Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Accessory",
        "Software",
        "Packaging"
    ],
    "Document Summary": "FDA 510(k) summary for CONTOUR NEXT ONE Blood Glucose Monitoring System with changes to strip packaging, user guide format, and outer carton configuration",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from fingertips or palm for self-testing by people with diabetes at home as an aid in monitoring diabetes control.",
    "fda_folder": "Clinical Chemistry"
}